Gut Peptides and Bone Remodeling in Children With Neuromuscular Disorders
NCT ID: NCT07254988
Last Updated: 2025-11-28
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
8 participants
INTERVENTIONAL
2023-03-24
2026-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
BASIC_SCIENCE
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Meal test
Oral liquid meal test
Meal test
Ingestion of an oral liquid meal (nutridrink), 3.3 mL/kg body weight.
Glucose dependent insulinotropic polypeptide (GIP) + Glucagon-like-peptide 2 (GLP-2)
Subcutaneous co-injection of GIP and GLP-2
GIP + GLP-2
Subcutaneous GIP + GLP-2 injection (1 mL containing 100 microgram GIP + 1 mL containing 400 microgram GLP-2).
Placebo
Subcutaneous injection of saline
Placebo
Subcutaneous saline injection (2 mL isotonic saline).
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Meal test
Ingestion of an oral liquid meal (nutridrink), 3.3 mL/kg body weight.
GIP + GLP-2
Subcutaneous GIP + GLP-2 injection (1 mL containing 100 microgram GIP + 1 mL containing 400 microgram GLP-2).
Placebo
Subcutaneous saline injection (2 mL isotonic saline).
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Confounding illnesses
* Pregnancy
* Allergy towards the components given on the test days
* Hgb\<6.5 mmol/L
10 Years
17 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Copenhagen
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Bolette Hartmann
Principal investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Mette Marie Rosenkilde
Role: STUDY_DIRECTOR
University of Copenhagen
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Rigshospitalet
Copenhagen, , Denmark
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Bolette Hartmann
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
TK-23
Identifier Type: -
Identifier Source: org_study_id